posted on 2017-12-18, 09:51authored byCatherine W. Karekezi
Oxamniquine, 6-hydroxymethyl-2-N-isopropylaminomethyl-7-nitro-1,2,3,4-
tetrahydroquinoline, is a potent schistosomicide used clinically in the treatment of
infections due to Schistosoma mansoni. Schistosomiasis is the second most
important tropical disease after malaria. Although oxamniquine is relatively well
tolerated, severe central nervous system (CNS) effects characterized by
convulsions, have been reported in a small percentage of the population treated
with this drug. [Continues.]
Funding
Association of Commonwealth Universities, Commonwealth Scholarship Commission.
This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 2.5 Generic (CC BY-NC-ND 2.5) licence. Full details of this licence are available at: http://creativecommons.org/licenses/by-nc-nd/2.5/
Publication date
1992
Notes
A Doctoral Thesis. Submitted in partial fulfilment of the requirements for the award of Doctor of Philosophy at Loughborough University.